PhaseBio Pharmaceuticals Inc
PB1046, a recombinant fusion protein combining vasoactive intestinal peptide (VIP) with an elastin-like peptide carrier for sustained pulmonary arterial hypertension treatment
- Sector
- Biotech
- Headquarters
- Malvern, PA
- Latest Form D
- $26M, Sep 2018
- Total capital
- $69M
- Grants
- $5.3M
- 4 awards
- 4.0× sector median 1 award
- Raised
- $64M
- 5 Form D · Sep 2018
- 97 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 9 granted · 31 pending
- 20× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓200920112013201520172019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension | $1,249,307 | |
| Private capital raised | Form D · SEC | $25,998,130 | |
| Federal grant | Department of Health and Human Services · Phase II · Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension | $2,497,273 | |
| Federal grant | Department of Health and Human Services · Phase II · Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension | $1,247,966 | |
| Federal grant | Department of Health and Human Services · Phase II · Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension | $297,765 | |
| Private capital raised | Form D · SEC | $6,615,000 | |
| Private capital raised | Form D · SEC | $20,000,000 | |
| Private capital raised | Form D · SEC | $10,120,000 | |
| Private capital raised | Form D · SEC | $999,999 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3386 | Ultragenyx Pharmaceutical Inc. | — | $109M |
| 3387 | BlueSphere Bio, Inc. | — | $56M |
| 3388 | Life Biosciences LLC | — | $54M |
| 3389 | PhaseBio Pharmaceuticals Inc | — | $64M |
| 3390 | OPUS GENETICS INC. | — | $47M |
| 3391 | CERo Therapeutics, Inc. | — | $45M |
| 3392 | Forte Biosciences | — | $44M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James BarrettDirector
- Ashutosh ChilkotiDirector · Executive Officer
- Guy FishDirector
- Michael GutchDirector
- Nancy HutsonDirector
- Robert IngramDirector
- Justin KleinDirector
- Thomas LaundonDirector · Executive Officer
Show all 21 people
- Caroline LoewyDirector
- Jonathan MowDirector · Executive Officer
- Bibhash MukhopadhyayDirector
- Christopher PriorDirector · Executive Officer
- Douglas ReedDirector
- Tyrell RiversDirector
- Craig RosenDirector
- John SharpExecutive Officer
- Will ShenDirector
- Joel SussmanExecutive Officer
- Clay ThorpDirector
- Linda TuftsDirector
- Asish XavierDirector
Patents
- Vasoactive Intestinal Peptide Fusion Proteins For The Treatment Of COVID-19application
- Elp Fusion Proteins Comprising Parathyroid Hormone For Controlled And Sustained Releaseapplication
- Methods And Compositions For Treating Muscle Disease And Disordersapplication
- Methods And Compositions For Treating Muscle Disease And Disordersgranted
- Methods And Compositions For Treating Cystic Fibrosisapplication
- Metalloenzyme Inhibitor Compoundsgranted
- Methods And Compositions For Treating Cystic Fibrosisgranted
- Metalloenzyme Inhibitor Compoundsgranted
- Use Of Modified Vasoactive Intestinal Peptides In The Treatment Of Hypertensiongranted
- Elp Fusion Proteins For Controlled And Sustained Releaseapplication
- Elp Fusion Proteins For Controlled And Sustained Releasegranted
- Methods And Compositions For Treating Muscle Disease And Disordersgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.